Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From David Lovett, on the Cloud Centric Investor Relations site.
DTC STATUS UPDATE - Wednesday 9th March 2011
Please accept my apologies readers for my lack of updates - I have been out of the country with little access to the blog writing backend of the website.
Anyway - our attorney is working with a Broker / Dealer to submit the required legal opinions to the DTC,
Whether this goes all the way to removing the CHILL ORDER, I am not sure as yet. I will update when I have more.
DL
People here need to chill. No pun intended.
At least we got an update today.
Things will eventually get worked out. Until then, pay more
attention to your other holdings.
I'll be doubling down at .0002 soon enough.
For my one daily post, I'll present you all with a riddle.
What do you get when you combine Myron Guslak, Marcus Segal and Helix?
*Hint. One of them sits in jail right now.
I would guess April. Nothing like the Springtime to kick things into gear.
It'll go soon enough. The military contracts are supposed to start kicking in this month. That will generate some working capital to give things a kickstart. How much capital, I dunno. Hopefully enough to at least launch the Nutritional Guide.
The truth to nearly every Helix question you guys have, is already out there in plain sight.
Put in the work and you'll find it. That's it for my one, allowable post for the day.
First time I've seen INTLN on the ask.
Perhaps as a result of new IR firm?
Or maybe I just have no clue.
Cheers
http://www.intlmarketmaking.com/
Well said Rick! Well said.
This drop in price for those that are in long term and accumulating, this is like Christmas!
Just filled. Canceled the the order and re-ordered it. 7500 shares filled immediately. Not too much, but enough to continue averaging down. Thank you UBSS for the gift of .0365
Yup. I guess I'll have to lower my quantity. Must be really thin.
I'll wait another 30 minutes.
Trying to get a buy order filled at .0365 for the past 30 minutes. Not filled yet. C'mon Man!
With a positive company PR, it will continue to rise. Short sellers will short it if there is no PR and profit takers will cash in or sell just enough so that they are only playing with house money. It then depends on who outnumbers who. Everything is very thin right now, on both the bid and the ask. The first 15 minutes of trading will determine the days direction.
My personal opinion is that it'll gap up a couple points to .0017-.0018. Will tap .0023-0024, early, and eventually go down to .0014 and then bounce back up to .0016, where it will close for the day.
Finally was able to make a play on friday in another company and now have some good powder to play with. Currently holding 350K shares to get my feet wet. Will be adding another 1.15 million soon for an even 1.5
Cheers to all.
Hey USA, Viking, I'll be more then happy to divulge the extra DD I have. But I'm done posting any DD I have on the general board. If you are both able to send private messages, send me one with your emails and I'll send you some extra stuff of what I got and what I will have shortly. I got put on HLXW probation for posting basher strategies. Lol! But now I can only post one thing per day. I believe this post counts as my 1 for Saturday.
Good luck.
Is it just me or do people here want confirmation on the OMRF thing.
As I post this, most of you that have read my previous posts know me to be long and supportive. All I want is confirmation that the turbines are in fact Helix brand. I have contacted OMRF and they can't confirm. The nice lady had no clue.
The editors of the article will not respond to my requests for confirmation. They have multiple Helix articles in the past, so i deem them to be bias.
In regards to Reinhold Ziegler, http://www.synergyii.com/, the designer of the OMRF, he seemed surprised that the contract was canceled to begin with. He asked me "where did you read the story that the Helix Wind turbines were cancelled?". He then continued to say, in regards to Helix, "Helix Wind's stock
is in the toilet. They have also been very inflexible in changing the way the turbines were mounted. We have many other turbines that we work with." I don't know what to make of that. The OMRF was developed with the Helix brand in mind since 2009. Months of testing went into the Helix brand to ensure very specific specifications were met. Its not like they can just go to another company and say, 'Lets use you'.
Helix issued an 8K saying the contract was canceled. If the contract was indeed canceled, they would have to issue another 8K stating that they got it back. That has yet to occur. Which leads me to believe that either the contract was never canceled to begin with or Helix decided not to report that they got it back, which is in violation of SEC rules. WTF!!!
What is going on here!!!! Fact is, somebody is lying.
Enough questions, for me at least, have been raised that I am forced to consider this a pump scheme, orchestrated possibly by Bluewater and IAB. Bluewater was granted a winning verdict in their case against Helix on january 22nd and Helix has yet to report that. (And yes, I have proof.) Bluewater have motive. They're guilty of it in the past and one of their guys associated with Helix sits in jail right now because of it. I have been in contact with Bluewater's lawyer and he stopped responding to me when i brought up the verdict.
I will be playing this as such and have my exit strategy set in motion. I will be exiting on Monday. Circumstances brought on during the day will determine the point of exit.
I hope everybody here makes a killing. But don't get too greedy. Lets hope for news over the weekend. Something to support the last few days of movement.
Yeah, Duma, I took over as moderator and have been modifying the page. It'll be an ongoing process.
As for the O/S I have listed, I believe, the 43.9 million number is the outstanding along with the preferred. Without it, its about 30.7 million.
Looks like a 'paint job' battle going on right now.
Here's another 350K. It all adds up.
I use the Level 2's on the OTC site
http://www.otcmarkets.com/stock/HLXW/quote
Too bad that NITE was the last one standing. Takes a lot of powder to get him to move.
Thanks for the info, but when it comes to these plays, I'm not really a chart follower. These things can change on a gust of wind, no pun intended.
However, if I do look at a chart for these things, I'll look at the accumulation and the Chaikin's volatility indicator.
Cheers and good luck.
Sure thing. I will let the board know when the issuance is completed.
Exactly. I find it rather amusing. With this company, most likely, people that bought on rumor and sold on news actually sold for a loss or a very small gain. Lol. Those people completely played that trading philosophy incorrectly. Normally, one plays that after the rumor shoots it up and the stock is at a good percentage above it's bottom.
Most likely it'll start trickling back up to .0015-.002 as the week goes by.
The patent will be issued to Helix in about 2 weeks. The Issuance will be announced either end of this week or early next.
The patent was dispatched to the FDC (Final Data Capture ) on February 11th. The FDC makes any updates necessary to the electronic file and places the allowed patent application in an issue. The average time that an allowed application is in the FDC process is 5 weeks. So, for Helix, it should be done in mid March.
The “Issue Notification” is mailed approximately 3 weeks prior to the issue date of the patent. So, for Helix, the issuance notification will take place between March 4th-7th.
Once the patent is in hand, perhaps we'll here something that moves the company forward.
Looks like amateur hour. Can't help but laugh. Big news so lets sell for a loss. Lol.
If you guys really want to find some interesting stuff, you would look into the world of Myron Gushlak of Bluewater Partners as well as Bluewater Partners as a whole, the people of IAB Island Ventures, Marcus Segal of Star Energy and Stargold Mines and how they all intertwine with each other. Then look at how all the above's histories intertwine with Helix. It can be a bit daunting and confusing, but in the end, eye opening.
Cheers
Latest 8K from the 15th shows them to still be incorporated in Nevada.
Another company would simply buy NIR's debt and EPGL's debt would merely pass hands. However, that may open doors to a better restructuring deal depending on who takes over the debt. Or it could go the other way. Its a crap shoot.
New article published on CardioBip
http://newshawksreview.com/hand-held-atrial-fibrillation-detection-no-wires-and-good-compliance/42233/
Nothing the CEO can do right now. His hands are tied. They have limited, to no working capital. Business is business. Until they get their debt restructured they are stuck in the starting blocks. And they won't get their debt restructured until the FBI and SEC completes their criminal probe of NIR, which is the root cause of the delay. Only then will we see any advancement in the current business plan and the PPS.
NewCardio Study Shows CardioBip Detects Recurrent Atrial Fibrillation Earlier and More Reliably than Periodic Holter Monitoring
Study to be Presented at the Heart Rhythm Society Annual Scientific Meeting in San Francisco This Spring
SANTA CLARA, CA (February 24, 2011) - PR Newswire - NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited by the Heart Rhythm Society (HRS) to present results of a recent clinical study showing that recurrent atrial fibrillation (AF) was accurately and timely detected in patients who used CardioBip™ for daily monitoring following catheter ablation procedures. The presentation, entitled "Long-term Intermittent Wireless Remote Monitoring of Reconstructed 12-Lead ECG in Post-Ablation AF Patients Using the CardioBip System", will be made at the 32nd Annual Scientific Sessions of the HRS, to be held in San Francisco, CA, May 4-7, 2011.
AF affects an estimated 1% of the worldwide population, with nearly three million AF patients in the US and six million AF patients in Europe. It is a serious medical condition that doubles mortality risk and increases risk of stroke by five-fold. Accordingly, such patients often need ambulatory monitoring to detect AF recurrences. Currently available AF monitoring devices have significant limitations, such as relatively few monitoring leads and the need to wear a device with attached wires and skin electrodes. CardioBip addresses these limitations as it does not employ any skin electrodes or wires. The handheld device conveniently records and wirelessly transmits information sufficient to reconstruct a full 12-lead ECG.
Vincent Renz, CEO of NewCardio, commented, "We are delighted to be presenting our latest CardioBip clinical study at the HRS Annual Scientific Meeting, a prestigious forum that is well-attended by cardiologists and electrophysiologists with a particular interest in novel solutions for long-term ambulatory cardiac monitoring. The exciting data from this study provide additional and very solid supporting evidence for our belief that CardioBip is exceptionally well-suited for long-term cardiac monitoring. There are more than 30 million patients - in the US and throughout the world - who have atrial fibrillation or other cardiac arrhythmias, and could benefit from using the CardioBip solution. We look forward to sharing the data with our HRS colleagues, and to building market awareness of CardioBip's efficacy, ease of use, and suitability for this important clinical need."
In the study, 21 patients who underwent catheter ablation for AF were given CardioBip devices and asked to provide daily transmissions for 60 days and additional transmissions whenever symptoms (such as palpitations or dizziness) developed. Patients also had 24-hour, continuous 12-lead ECG recordings (Holter monitors [HM]), a commonly-used method for AF surveillance, at 30 and 60 days post-procedure. Both CardioBip and HM data were reviewed by two independent, blinded cardiologists.
All 21 patients completed the full 60-day follow-up period and showed good compliance throughout, making an average of 2.2 transmissions per day. Twenty of 21 patients had at least one episode of recurrent AF detected by CardioBip. Most of these episodes were asymptomatic. Six of the 20 patients also had occurrence of atrial flutter (AFLT) detected. In contrast, only four and two patients had recurrent AF and AFLT detected by 12-lead HM, respectively. In all these six patients, AF and AFLT had already been detected by CardioBip - an average of 27 days earlier than detection by 12-lead HM. All symptomatic CardioBip transmissions were correlated with at least one rhythm irregularity (e.g. AF, AFLT, or premature beats).
Dr. Dorin Panescu, PhD, NewCardio's Chief Technical Officer, commented, "This is the third clinical study showing that CardioBip is an effective, accurate and patient-friendly solution for long-term monitoring of cardiac conditions. In particular, the study data show that CardioBip has the potential to contribute to clinical management of patients affected by atrial fibrillation."
Dr. Panescu continued, "NewCardio is committed to strengthening the CardioBip solution and to protecting its respective intellectual property worldwide. In addition to filing several CardioBip-related patent applications with the US Patent Office, NewCardio has aggressively filed respective PCT patent applications and had been issued core CardioBip patents in several other countries."
Each year, the HRS receives thousands of submissions from outstanding investigators throughout the world, but selects only about one-third for presentation. This is the third successive year that the HRS had invited scientists to present results from studies that used NewCardio's 3-D ECG solutions.
In order to increase the A/S, they need a shareholder vote. Have shareholders already voted on this in the past?
Guess its a matter of if and when with regards to the AS increase.
Until then, lets hope for the bounce play.
http://pennystockgurus.blogspot.com/
Takes a lot to get it up. Next to nothing to bring it down.
NewCardio Study of my3KG Accuracy in Diabetic Patients to be Presented at the American College of Cardiology National Meeting
Study shows my3KG significantly improves sensitivity for
detection of myocardial infarction in diabetics
SANTA CLARA, CA (February 15, 2011) - PR Newswire - NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited by the American College of Cardiology (ACC) to present the results of a key study showing that NewCardio's urgent care solution, my3KG™, had substantially greater accuracy than expert cardiologists' interpretation of standard 12-lead ECG (12L ECG) in diagnosing Acute Myocardial Infarction (AMI) in diabetic patients. The presentation will be made at the 60th Annual ACC Scientific Meeting to be held in New Orleans, LA, April 2-5, 2011.
Accurate and timely diagnosis of AMI is notoriously difficult in diabetics, largely because the standard 12L ECG is often inaccurate, inconclusive or non-diagnostic in this patient group. To address this problem, investigators at the University of Kansas Medical Center, in collaboration with NewCardio physician-scientists, obtained detailed clinical and 12L ECG data on 155 consecutive diabetic patients with suspected AMI, and evaluated the diagnostic performance of my3KG in this patient group. The study, which was completed in October 2010, showed that my3KG had 42% greater sensitivity than expert cardiologist interpretation of 12L ECG for early detection of AMI, with equal or better specificity.
Diabetics with AMI represent a very large and growing patient group, and currently affect over 10% of adults in the US. Moreover, the incidence of AMI is two to four times greater in diabetics than in the general population, according to the American Diabetes Association and the American Heart Association. NewCardio believes use of my3KG in this patient group may facilitate more accurate and timely diagnosis of AMI in diabetic patients, and may lead to improved clinical outcomes.
Dr. Ihor Gussak, MD, PhD, NewCardio's Chief Medical Officer and a Fellow of the ACC, commented, "We are delighted to present our study results at this prominent and well-attended meeting. This professional cardiology forum provides us with a great opportunity to share exciting data from our most recent clinical study, which shows that the my3KG can substantially improve diagnosis of AMI in diabetics. Accurate and timely diagnosis of AMI in diabetics has been a particularly difficult problem for cardiologists and emergency physicians, and we believe our study shows that my3KG can play a major role in solving it. NewCardio is committed to developing its platform technology and deploying specific solutions with the goal of adding value across the entire spectrum of cardiology, and ultimately saving lives."
NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12L ECG. NewCardio is developing the my3KG solution for urgent diagnosis of serious cardiac conditions, including AMI. In clinical studies to date, the my3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities). Accordingly, the Company believes that its innovative my3KG solution will substantially improve diagnostic timing and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients. The my3KG is not currently marketed for sale in the U.S. The Company intends to file an application for 510(k) approval with the FDA in 2011/2012.
About the American College of Cardiology
The American College of Cardiology is a 39,000-member nonprofit medical society comprised of physicians and allied health professionals. The College is a leader in the formulation of health policy, standards and guidelines, operates and maintains national cardiovascular patient registries, and supports cardiovascular research and professional education.
Doubt it. Most people are 1-2 tick flippers. They'll sell at 2
That assumption would be incorrect. The annual report will come out before the quarterly. The Annual is due March 31st. As far as the other stuff goes, they'll apply for the 510's when they seal a deal with a strategic partner for funding. Unfortunately, all they can say about that right now is that they are still in negotiations. Just gotta be patient.